同日重复静脉注射CT对比剂或联合使用CT与MRI对比剂的安全性:一项动物研究
该动物研究将56只大鼠分为8组,探讨在初次静脉注射碘对比剂后24小时内追加碘对比剂或钆对比剂对肾脏的分子与功能影响。结果显示重复注射CT对比剂组血清肌酐显著高于单次注射组,而追加MR对比剂组与单次注射组无显著差异。作者认为重复增强CT之间可能需要足够时间间隔(可能超过24小时),而同一天内CT增强后行MRI增强可能不引起临床显著的肾损伤。
要点
- 重复注射CT对比剂后血清肌酐显著升高,提示肾功能可能恶化。
- 追加MR对比剂后血清肌酐、胱抑素C和丙二醛水平与单次CT对比剂组无显著差异。
- 肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白的mRNA及蛋白水平在各追加对比剂组间无显著差异。
核心结论
- 重复增强CT之间可能需要足够的时间间隔(可能超过24小时)以避免肾功能恶化;而同一天内CT增强后行MRI增强可能不引起临床显著的肾损伤。
研究设计与样本
- 动物研究,56只Sprague-Dawley雄性大鼠等分为8组:阴性对照组、阳性对照组(单次注射CT对比剂)以及在初次CT对比剂注射后2、4或24小时追加CT或MR对比剂组;经尾静脉注射12 µL/g碘对比剂或0.47 µL/g钆对比剂;检测血清尿素氮、肌酐、胱抑素C和丙二醛水平,以及肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白的mRNA和蛋白水平。
诊断标准与关键数值
- 重复注射CT对比剂组血清肌酐显著高于阳性对照组:阳性对照组0.21 ± 0.02 mg/dL,2小时间隔组0.40 ± 0.02 mg/dL,4小时间隔组0.34 ± 0.03 mg/dL,24小时间隔组0.41 ± 0.10 mg/dL,P < 0.001。
- 阳性对照组与重复注射CT对比剂组之间平均胱抑素C和丙二醛水平无显著差异:胱抑素C P = 0.256-0.362;丙二醛 P > 0.99。
- 追加MR对比剂组与阳性对照组相比,血清肌酐(P > 0.99)、胱抑素C(P = 0.262)和丙二醛(P = 0.139-0.771)水平无显著变化。
- 追加CT或MR对比剂各组间肾损伤分子-1和中性粒细胞明胶酶相关脂质运载蛋白的mRNA及蛋白水平无显著差异(P > 0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate molecular and functional consequences of additional exposures to iodine- or gadolinium-based contrast agents within 24 hours from the initial intravenous administration of iodine-based contrast agents through an animal study.
MATERIALS AND METHODS: Fifty-six Sprague-Dawley male rats were equally divided into eight groups: negative control, positive control (PC) with single-dose administration of CT contrast agent, and additional administration of either CT or MR contrast agents 2, 4, or 24 hours from initial CT contrast agent injection. A 12 µL/g of iodinated contrast agent or a 0.47 µL/g of gadolinium-based contrast agent were injected into the tail vein. Serum levels of blood urea nitrogen, creatinine, cystatin C (Cys C), and malondialdehyde (MDA) were measured. mRNA and protein levels of kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) were evaluated.
RESULTS: Levels of serum creatinine (SCr) were significantly higher in repeated CT contrast agent injection groups than in PC (0.21 ± 0.02 mg/dL for PC; 0.40 ± 0.02, 0.34 ± 0.03, and 0.41 ± 0.10 mg/dL for 2-, 4-, and 24-hour interval groups, respectively; P < 0.001). There was no significant difference in the average Cys C and MDA levels between PC and repeated CT contrast agent injection groups (Cys C, P = 0.256-0.362; MDA, P > 0.99). Additional doses of MR contrast agent did not make significant changes compared to PC in SCr (P > 0.99), Cys C (P = 0.262), and MDA (P = 0.139-0.771) levels. mRNA and protein levels of KIM-1 and NGAL were not significantly different among additional CT or MR contrast agent groups (P > 0.05).
CONCLUSION: A sufficient time interval, probably more than 24 hours, between repeated contrast-enhanced CT examinations may be necessary to avoid deterioration in renal function. However, conducting contrast-enhanced MRI on the same day as contrast-enhanced CT may not induce clinically significant kidney injury.
引用
- Bae H, Oh H, Park GB, et al. Safety of Administering Intravenous CT Contrast Agents Repeatedly or Using Both CT and MRI Contrast Agents on the Same Day: An Animal Study. Korean J Radiol. 2024. PMID: 38413110. doi:10.3348/kjr.2023.0712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。